FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy

Despite strong data, Alnylam says it will now abandon efforts to expand the drug’s indication in the United States.

Related Keywords

Ronald Witteles ,Renal Drugs Advisory Committee ,Drug Administration On ,Stanford Amyloid Center ,Md Stanford University School Of Medicine ,Alnylam Pharmaceuticals ,Drug Administration ,Kansas City Cardiomyopathy Questionnaire ,Stanford University School ,Complete Response Letter ,